We are delighted to announce the projects and organisations receiving grants as part of the latest round of the Initiatives in Lung Cancer Care (ILC2) program.
ILC2 is a global funding program that supports patient and caregiver organisations to deliver transformative projects focused on addressing gaps in lung cancer service delivery across the world.
”The programs receiving grants are bold, innovative and patient-focused with the potential for both immediate learnings and long-term expansion.”
David LeDuc, Associate Director of Oncology Patient Affairs at AstraZeneca, said, “As a committee, we were so pleased to receive a wide range of high-quality applications representing the breadth and depth of work being done by the patient advocacy community across the globe.”
He added, “The programs receiving grants are bold, innovative and patient-focused with the potential for both immediate learnings and long-term expansion. Each program selected outlines a unique approach – including efforts to improve rates of early diagnosis, increased psychological support for lung cancer patients, and digital innovation to enhance access to care – to address different aspects of the patient experience.”
At present, patient outcomes vary greatly across countries, with five-year survival rates ranging from approximately 3% to 33% worldwide1, underpinning the global focus of the ILC2 scheme to improve lung cancer patient outcomes.
Mohit Manrao, Vice-President and Global Franchise Head for Lung Cancer at AstraZeneca, said, “We are proud to fund the great work of grassroots patient organisations worldwide, which have shown the utmost dedication in seeking improvements for people with lung cancer.
”Empowering patient and caregiver organisations through the ILC2 programme is an important part of the Lung Ambition Alliance’s aspiration to eliminate lung cancer as a cause of death.”
See below for this year’s ILC2 awardees – GLCC member organisations in BOLD.
Organisation: Fundacion Pacientes de Cancer de Pulmón
Project Title: The path to diagnosis
Country: Argentina
Organisation: Thoracic Oncology Group of Australasia Ltd
Project Title: Enabling teletrials to provide access to clinical trials for regional and remote Australians
Country: Australia
Organisation: European Network for Smoking and Tobacco Prevention (ENSP)
Project Title: BREATHE – Breaking tobacco addiction for improved lung cancer care
Country: Belgium
Organisation: Instituto Oncoguia (Oncoguia Institute)
Project Title: Understanding the Quality of Life of Patients Living with Metastatic Lung Cancer in Brazil
Country: Brazil
Organisation: National Patients’ Organization
Project Title: HELPers – lung cancer assistants
Country: Bulgaria
Organisation: FairLife Lung Cancer Care
Project Title: SuppoRting lung cancEr pATients in Greece stage II – bREATh-II
Country: Greece
Organisation: Polskie Amazonki Ruch Społeczny
Project Title: Crisis Center for lung cancer patients – Improvement of early lung cancer detection in Poland
Country: Poland
Organisation: Autonomous non-profit organization for psychological assistance and social counselling “Project Co-operate (Socially Responsible Action)”
Project Title: All-Russia program for efficient communication between lung cancer patients and health care providers
Country: Russia
Organisation: Udruženje Građana Za Borbu Protiv Raka Pluća “Punim Plućima”
Project Title: NO WAITING
Country: Serbia
Organisation: Asociación Española de Afectados de Cáncer de Pulmón
Project Title: AEACaP talks
Country: Spain
Organisation: Dusty Joy Foundation
Project Title: Small Cell Lung Cancer (SCLC) Virtual Group Meetings
Country: USA
1Allemani C, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018 Mar 17;391(10125):1023-75.
Date of Preparation: January 2022 | Document ID: Z4-40879
